retatrutide to tirzepatide vs. Tirzepatide: The Next-Gen GLP-1 Showdown Switching from tirzepatide to retatrutide:

Food & Drug Administration (FDA) for general medical use

These effects on energy balance complement incretin-mediated appetite suppression, facilitating greater weight loss

Systematic monitoring throughout the GLP-1 journey enables clinicians to assess therapeutic response, identify adverse effects early, and make evidence-based adjustments to optimize outcomes

Cardiovasc Endocrinol Metab 2023

Provider review A licensed medical provider reviews your intake and determines what's right for you

Obesity should be treated like a chronic disease, and patients must continue the medication long-term to sustain the results achieved from the medication